Selection of oral contraceptives or hormone replacement therapy: Patient communication and counseling issues

American Journal of Obstetrics and Gynecology

Volumn 185, Issue 2 SUPPL., 2001, Pages

  La Valleur, June ^a   Wysocki, Susan ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b National Association of Nurse Practitioners in Women's Health   (United States)

Author keywords

Communication; Counseling; Hormone replacement therapy; Oral contraceptives

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ARTICLE; DRUG FORMULATION; HEALTH HAZARD; HORMONE SUBSTITUTION; INTERPERSONAL COMMUNICATION; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0034878985     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2001.116523     Document Type: Article

References (52)

1. Trends in contraceptive use in the United States: 1982-1995
2. Use of hormone replacement therapy by postmenopausal women in the United States
3. Oral contraceptive compliance and its role in the effectiveness of the method
4. Continuation of postmenopausal hormone replacement therapy: Comparison of cyclic versus continuous combined schedules
5. Compliance with contraceptives and other treatments
6. Relationship between medication compliance and medical outcomes
7. Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation
8. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy
9. Unintended pregnancy in the United States
10. Patient education and understanding: A critical review
11. Physician-patient interaction in reproductive counseling
12. Oral contraceptive risk assessment: A survey of 247 educated women
13. Perception of contraceptive effectiveness and health effects of oral contraception
14. Breast cancer and hormonal contraceptives: Collaborative breast cancer reanalysis of individual data on 53,297 women with and 100,239 women without breast cancer from 54 epidemiological studies
15. Endometrial cancer and combined oral contraceptives
16. Risk of endometrial cancer in relation to use of combined oral contraceptives: A pracititioner's guide to meta-analysis
17. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer
18. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives
19. Oral contraceptives and endometrial cancer
20. The reduction in risk of ovarian cancer associated with oral-contraceptive use
21. Cardiovascular disease and steroid hormone contraception
22. Stroke in users of low-dose oral contraceptives
23. Clinical comparison of triphasic norgestimate/35 μg ethinyl estradiol and monophasic norethindrone acetate/20 μg ethinyl estradiol
24. The effect of 20 μg ethinyl estradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women
25. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris
26. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial
27. The perimenopause: A critical time in a woman's life
28. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis
29. Health maintenance for perimenopausal women
30. Oral contraceptives and bone mineral density: A population-based study
31. Oral-contraceptive use and risk of hip fracture: A case-control study
32. Low-dose oral contraceptives and bone mineral density: An evidence-based analysis
33. Bone-sparing properties of oral contraceptives
34. The normal menopause transition
35. Laboratory criteria for menopause in women using oral contraceptives
36. When is it safe to switch from oral contraceptives to hormonal replacement therapy?
37. The North American Menopause Society 1998 Menopause Survey. Part II: Counseling about hormone replacement therapy: Association with socioeconomic status and access to medical care
38. The North American Menopause Society 1998 Menopause Survey. Part I: Postmenopausal women's perceptions about menopause and midlife
39. Higher levels of plasma estradiol and testosterone in healthy elderly men compared with age-matched women may protect aspects of explicit memory
40. Endogenous estrogen levels and Alzheimer's disease among postmenopausal women
41. Patient-specific decisions about hormone replacement therapy in postmenopausal women
42. Treatment of postmenopausal osteoporosis with transdermal estrogen
43. Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis
44. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
45. Risk of venous thromboembolism in users of hormone replacement therapy
46. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
47. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
48. Use of progestogen therapy
49. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial
50. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause
51. Achieving long-term continuance of menopausal ERT/HRT: Consensus opinion of The North American Menopause Society